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Macrophage activation syndrome (MAS) is a life-
threatening complication of inflammatory disease,
occurring secondary to a complex interplay of genetic
factors, drugs, infectious agents and immunological
anomalies. Early identification and aggressive treatment
are mandatory to prevent fatal evolution.
Precipitating factors should be looked for and eventually
removed such as infections (leishmania, EBV, Parvo
B19…) or drug exposure. Epstein Barr Virus (EBV) is a
major cause of MAS and anti-EBV therapies can be help-
ful to control MAS.
First line therapies usually include high-dose steroids
associated to cyclosporine. In the context of primary
hemophagocytic lymphohistiocytosis (HLH), bone marrow
transplantation is the only treatment able to cure the dis-
ease. In inflammatory disease with secondary HLH, a few
case reports indicate an efficacy of anti-cytokine treatment
(anti-IL1, anti-IL6, anti-TNFa). However, a role of these
cytokines in MAS development remains unproven. To
investigate whether the IL-1 pathway might contribute to
MAS, we compared IL-1RA-/- to wild type mice after sti-
mulation with CpG, a TLR9 activator. TLR9-induced
MAS was similar in the two groups, suggesting that IL-1
excess is not a major inducer of MAS. More interestingly,
recent data implicate IFNg as a crucial factor in MAS
onset. Thus, the inhibition of secreted IFNg might repre-
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